Clinical observation of nalmefene in massive cerebral infarction

Hou Weichen; Fan jia; Liu Qun

doi:10.3760/cma.j.issn.1673-4777.2014.08.018

Abstract：Objective To assess their clinical effects and prognosis influence of nalmefene treated for middle cerebral artery infarction.Methods Totally 100 middle cerebral artery infarction patients were enrolled in this study and divided to nalmefene group and control group.Patients in both groups were treated by basic treatment.Nalmefene group was treated by nalmefene.Before and 10 days after treatment,Glasgow coma scale(GCS),National Institutes of Health Stroke Scale(NIHSS),matrix metallopro teinase 9(MMP-9) and perfusion weighted imaging(PWI) were analyzed.Results ①The GCS score of nalmefene group was 7.2 ± 2.3 before medication and 9.5 ± 2.9 after medication.The control group was 7.1 ± 1.9 before medication and 8.1-± 2.7 after medication (P ＜ 0.05).②The NIHSS score of treatment group was 22 ± 4 before medication and 17 ± 5 after medication.The control group was 23 ± 4 before medication and 20 ± 5 after medication (P ＜ 0.05).③After treatment of 10 days,MMP-9 concentration in nalmefene group was significantly lower than that in the control group(P ＜ 0.05).④ In the treatment of 10 days,in PWI of nalmefene group,these patients' cerebral blood flow(CBF) large range increased than the control group,these patients' mean transit time(MTT) obviously reduced than the control group.The difference was statistically significant (P ＜ 0.05).Conclusions Nalmefene can significantly improve the prognosis of the brain artery infarction patients with disturbance of consciousness and nerve dysfunction.Nalmefene can improve blood flow in the brain artery infarction patients.Nalmefene can reduce inflammatory factor levels of MMP-9; nalmefene may be an option of the treatment of acute cerebral infarction.Nalmefene may improve the prognosis of patient.